2021
DOI: 10.1016/j.cvfa.2021.03.008
|View full text |Cite
|
Sign up to set email alerts
|

Evidence Base for Treatment of Infectious Bovine Keratoconjunctivitis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(1 citation statement)
references
References 23 publications
0
1
0
Order By: Relevance
“…Economic impacts have been insufficiently studied but costs in the US alone likely are in the hundreds of millions of dollars each year [1]. The only antibiotics with label approval for IBK treatment in the US are oxytetracycline and tulathromycin, which raises concerns for increased frequencies of bacteria with antimicrobial resistance (AMR) to these antibiotics in cattle [8][9][10].…”
Section: Introductionmentioning
confidence: 99%
“…Economic impacts have been insufficiently studied but costs in the US alone likely are in the hundreds of millions of dollars each year [1]. The only antibiotics with label approval for IBK treatment in the US are oxytetracycline and tulathromycin, which raises concerns for increased frequencies of bacteria with antimicrobial resistance (AMR) to these antibiotics in cattle [8][9][10].…”
Section: Introductionmentioning
confidence: 99%